Raunak Shrestha, PhD
Cited by
Cited by
Pan-cancer analysis of whole genomes
Nature 578 (7793), 82-93, 2020
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
E Rheinbay, MM Nielsen, F Abascal, JA Wala, O Shapira, G Tiao, ...
Nature 578 (7793), 102-111, 2020
BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma
R Shrestha, N Nabavi, YY Lin, F Mo, S Anderson, S Volik, HH Adomat, ...
Genome Medicine 11 (1), 8, 2019
Pathway and network analysis of more than 2500 whole cancer genomes
MA Reyna, D Haan, M Paczkowska, LPC Verbeke, M Vazquez, ...
Nature communications 11 (1), 729, 2020
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer
AW Wyatt, F Mo, K Wang, B McConeghy, S Brahmbhatt, L Jong, ...
Genome biology 15, 1-14, 2014
Ultra high-dimensional nonlinear feature selection for big biological data
M Yamada, J Tang, J Lugo-Martinez, E Hodzic, R Shrestha, H Ouyang, ...
IEEE Transactions on Knowledge and Data Engineering, 2018
HIT'nDRIVE: Patient-specific multi-driver gene prioritization for precision oncology
R Shrestha, E Hodzic, T Sauerwald, P Dao, K Wang, J Yeung, ...
Genome Research, 2017
High-throughput detection of RNA processing in bacteria
EE Gill, LS Chan, GL Winsor, N Dobson, R Lo, SJ Ho Sui, BK Dhillon, ...
BMC genomics 19, 1-20, 2018
BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
ISU Luk, R Shrestha, H Xue, Y Wang, F Zhang, D Lin, A Haegert, R Wu, ...
Clinical cancer research 23 (6), 1542-1551, 2017
Well-Differentiated Papillary Mesothelioma of the Peritoneum is Genetically Distinct from Malignant Mesothelioma
R Shrestha, N Nabavi, S Volik, S Anderson, A Haegert, B McConeghy, ...
Cancers 12 (6), 2020
An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer
R Das, M Sjöström, R Shrestha, C Yogodzinski, EA Egusa, LN Chesner, ...
Nature Communications 12 (1), 4601, 2021
Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability
R Shrestha, ML Fernandez, A Dawson, J Hoenisch, S Volik, YY Lin, ...
Cancer Research, 2021
The 5-hydroxymethylcytosine landscape of prostate cancer
M Sjöström, SG Zhao, S Levy, M Zhang, Y Ning, R Shrestha, A Lundberg, ...
Cancer Research 82 (21), 3888-3902, 2022
Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma
NM D’Costa, MR Lowerison, PA Raven, Z Tan, ME Roberts, R Shrestha, ...
Journal of Experimental & Clinical Cancer Research 39, 1-16, 2020
Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma
NM D’Costa, D Cina, R Shrestha, RH Bell, YY Lin, H Asghari, ...
Scientific Reports 10 (1), 2026, 2020
Deep genomic signature for early metastasis prediction in prostate cancer
H Sharifi-Noghabi, Y Liu, N Erho, R Shrestha, M Alshalalfa, E Davicioni, ...
BioRxiv, 276055, 2018
Predicting cancer drug TARGETS-treatment response generalized elastic-neT signatures
NR Rydzewski, E Peterson, JM Lang, M Yu, S Laura Chang, M Sjöström, ...
NPJ genomic medicine 6 (1), 76, 2021
HIT’nDRIVE: Multi-Driver Gene Prioritization based on Hitting Time
R Shrestha, E Hodzic, J Yeung, K Wang, T Sauerwald, P Dao, ...
Autoantibody landscape in patients with advanced prostate cancer
WS Chen, WA Haynes, R Waitz, K Kamath, A Vega-Crespo, R Shrestha, ...
Clinical Cancer Research 26 (23), 6204-6214, 2020
Identification of Conserved Evolutionary Trajectories in Tumors
E Hodzic, R Shrestha, S Malikic, CC Collins, K Litchfield, S Turajlic, ...
Bioinformatics 36 (Supplement_1), i427-i435, 2020
The system can't perform the operation now. Try again later.
Articles 1–20